AngioDynamics (ANGO) Competitors $9.57 +0.06 (+0.63%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$9.56 -0.01 (-0.05%) As of 05/21/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ANGO vs. IART, OFIX, SRDX, ARAY, RMTI, RSLS, ABT, ISRG, BSX, and SYKShould you be buying AngioDynamics stock or one of its competitors? The main competitors of AngioDynamics include Integra LifeSciences (IART), Orthofix Medical (OFIX), Surmodics (SRDX), Accuray (ARAY), Rockwell Medical (RMTI), ReShape Lifesciences (RSLS), Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Boston Scientific (BSX), and Stryker (SYK). These companies are all part of the "health care equipment" industry. AngioDynamics vs. Integra LifeSciences Orthofix Medical Surmodics Accuray Rockwell Medical ReShape Lifesciences Abbott Laboratories Intuitive Surgical Boston Scientific Stryker Integra LifeSciences (NASDAQ:IART) and AngioDynamics (NASDAQ:ANGO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, community ranking, risk, institutional ownership and earnings. Do institutionals & insiders hold more shares of IART or ANGO? 84.8% of Integra LifeSciences shares are held by institutional investors. Comparatively, 89.4% of AngioDynamics shares are held by institutional investors. 3.5% of Integra LifeSciences shares are held by insiders. Comparatively, 5.4% of AngioDynamics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media prefer IART or ANGO? In the previous week, Integra LifeSciences had 4 more articles in the media than AngioDynamics. MarketBeat recorded 9 mentions for Integra LifeSciences and 5 mentions for AngioDynamics. AngioDynamics' average media sentiment score of 1.71 beat Integra LifeSciences' score of 0.57 indicating that AngioDynamics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integra LifeSciences 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AngioDynamics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more risk & volatility, IART or ANGO? Integra LifeSciences has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Does the MarketBeat Community believe in IART or ANGO? Integra LifeSciences received 69 more outperform votes than AngioDynamics when rated by MarketBeat users. However, 61.26% of users gave AngioDynamics an outperform vote while only 56.72% of users gave Integra LifeSciences an outperform vote. CompanyUnderperformOutperformIntegra LifeSciencesOutperform Votes43956.72% Underperform Votes33543.28% AngioDynamicsOutperform Votes37061.26% Underperform Votes23438.74% Which has stronger earnings & valuation, IART or ANGO? Integra LifeSciences has higher revenue and earnings than AngioDynamics. Integra LifeSciences is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntegra LifeSciences$1.62B0.61$67.74M-$0.38-33.39AngioDynamics$283.32M1.37-$184.35M-$1.01-9.48 Do analysts rate IART or ANGO? Integra LifeSciences currently has a consensus target price of $18.63, indicating a potential upside of 46.77%. AngioDynamics has a consensus target price of $14.00, indicating a potential upside of 46.29%. Given Integra LifeSciences' higher probable upside, research analysts clearly believe Integra LifeSciences is more favorable than AngioDynamics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Integra LifeSciences 4 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.78AngioDynamics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is IART or ANGO more profitable? Integra LifeSciences has a net margin of -0.42% compared to AngioDynamics' net margin of -79.38%. Integra LifeSciences' return on equity of 12.35% beat AngioDynamics' return on equity.Company Net Margins Return on Equity Return on Assets Integra LifeSciences-0.42% 12.35% 4.82% AngioDynamics -79.38%-7.26%-4.78% SummaryIntegra LifeSciences beats AngioDynamics on 10 of the 17 factors compared between the two stocks. Get AngioDynamics News Delivered to You Automatically Sign up to receive the latest news and ratings for ANGO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANGO vs. The Competition Export to ExcelMetricAngioDynamicsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$388.61M$4.50B$5.38B$8.39BDividend YieldN/A43.63%5.21%4.10%P/E Ratio-1.7029.4326.8019.71Price / Sales1.3767.72389.70117.54Price / Cash2.4151.0838.2534.62Price / Book1.876.236.804.50Net Income-$184.35M$68.16M$3.23B$248.18M7 Day Performance4.36%-0.19%1.52%0.23%1 Month Performance2.90%19.19%10.04%12.39%1 Year Performance51.42%21.47%16.73%7.07% AngioDynamics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANGOAngioDynamics4.5053 of 5 stars$9.57+0.6%$14.00+46.3%+63.3%$388.61M$283.32M-1.70760News CoveragePositive NewsGap UpIARTIntegra LifeSciences4.4517 of 5 stars$13.55-0.1%$18.63+37.5%-53.7%$1.05B$1.62B-150.543,720Gap DownOFIXOrthofix Medical3.44 of 5 stars$12.06-0.7%$23.33+93.5%-20.5%$470.61M$804.53M-3.851,090Positive NewsSRDXSurmodics4.2226 of 5 stars$29.48+3.1%$43.00+45.9%-16.6%$408.67M$121.58M-29.19450Positive NewsARAYAccuray2.1303 of 5 stars$1.62flatN/A+6.6%$166.88M$465.25M-32.401,040Analyst DowngradeGap UpRMTIRockwell Medical4.1176 of 5 stars$1.04+3.0%$4.00+284.6%-44.7%$35.54M$97.73M-20.80300Analyst RevisionRSLSReShape Lifesciences0.5667 of 5 stars$6.47+3.0%N/A-98.1%$4.78M$8.01M-0.0250News CoverageEarnings ReportGap DownABTAbbott Laboratories4.8795 of 5 stars$135.52+0.5%$142.59+5.2%+29.3%$235.78B$42.34B17.72115,000Positive NewsISRGIntuitive Surgical4.2764 of 5 stars$561.63-0.3%$598.95+6.6%+36.0%$201.30B$8.71B87.6212,100Positive NewsBSXBoston Scientific4.1953 of 5 stars$106.61+0.5%$114.74+7.6%+38.3%$157.72B$17.55B85.2945,000Positive NewsOptions VolumeSYKStryker4.9288 of 5 stars$394.63+0.1%$427.05+8.2%+15.0%$150.63B$23.22B50.8551,000Positive News Related Companies and Tools Related Companies Integra LifeSciences Competitors Orthofix Medical Competitors Surmodics Competitors Accuray Competitors Rockwell Medical Competitors ReShape Lifesciences Competitors Abbott Laboratories Competitors Intuitive Surgical Competitors Boston Scientific Competitors Stryker Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANGO) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AngioDynamics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AngioDynamics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
